Literature DB >> 17226859

Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas.

Jason L Rowand1, Grace Martin, Gerald V Doyle, M Craig Miller, Michael S Pierce, Mark C Connelly, Chandra Rao, Leon W M M Terstappen.   

Abstract

BACKGROUND: A lack of standardized assays and consensus of cell definition has lead to a wide variation in the reported range of circulating endothelial cells (CECs).
METHODS: An automated rare cell analysis system was used to enumerate nucleated, CD146+/CD105+/CD45- CECs in 4 mL of blood.
RESULTS: Recoveries of spiked HUVECs were linear over a range of 0-1,241 cells (R2>or=0.99) with recoveries of >or=70% at each spike level. Correlation coefficient values for interoperator variability and duplicate sample variation were (R2=0.99 and 0.90), respectively. Correlation of CEC counts between tubes 1-2 and 2-3 drawn from the same subject in sequence differed (R2=0.48 and 0.63, respectively). The normal CEC reference range established in 249 healthy donors was 1-20 CECs/mL blood. CEC counts were significantly higher in the 206 metastatic carcinoma patients (P<0.0001).
CONCLUSION: CECs can be accurately and reproducibly enumerated in blood and are elevated in metastatic carcinomas compared with healthy donors. Phlebotomy procedures can affect endothelial cell counts. Copyright (c) 2007 International Society for Analytical Cytology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17226859     DOI: 10.1002/cyto.a.20364

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  45 in total

1.  Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

Authors:  Mariangela Manzoni; Sara Mariucci; Sara Delfanti; Bianca Rovati; Monica Ronzoni; Fotios Loupakis; Silvia Brugnatelli; Carmine Tinelli; Eugenio Villa; Alfredo Falcone; Marco Danova
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

Review 2.  Challenges in circulating tumor cell detection by the CellSearch system.

Authors:  Kiki C Andree; Guus van Dalum; Leon W M M Terstappen
Journal:  Mol Oncol       Date:  2015-12-25       Impact factor: 6.603

3.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

4.  Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction.

Authors:  Kelly Bethel; Madelyn S Luttgen; Samir Damani; Anand Kolatkar; Rachelle Lamy; Mohsen Sabouri-Ghomi; Sarah Topol; Eric J Topol; Peter Kuhn
Journal:  Phys Biol       Date:  2014-01-09       Impact factor: 2.583

5.  Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.

Authors:  Steven G DuBois; Diana Stempak; Bing Wu; Reza Bayat Mokhtari; Rakesh Nayar; Katherine A Janeway; Robert Goldsby; Holcombe E Grier; Sylvain Baruchel
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

6.  Characterization of circulating endothelial cells in acute myocardial infarction.

Authors:  Samir Damani; Andrea Bacconi; Ondrej Libiger; Aparajita H Chourasia; Rod Serry; Raghava Gollapudi; Ron Goldberg; Kevin Rapeport; Sharon Haaser; Sarah Topol; Sharen Knowlton; Kelly Bethel; Peter Kuhn; Malcolm Wood; Bridget Carragher; Nicholas J Schork; John Jiang; Chandra Rao; Mark Connelly; Velia M Fowler; Eric J Topol
Journal:  Sci Transl Med       Date:  2012-03-21       Impact factor: 17.956

Review 7.  Isolating and defining cells to engineer human blood vessels.

Authors:  P J Critser; S L Voytik-Harbin; M C Yoder
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

8.  Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Authors:  Lynn Symonds; Hannah Linden; Vijayakrishna Gadi; Larissa Korde; Eve Rodler; Julie Gralow; Mary Redman; Kelsey Baker; Quan Vicky Wu; Isaac Jenkins; Brenda Kurland; Mitchell Garrison; Julie Smith; Jeanne Anderson; Carol Van Haelst; Jennifer Specht
Journal:  Clin Breast Cancer       Date:  2018-12-14       Impact factor: 3.225

9.  Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Authors:  P Hamberg; N Steeghs; W J Loos; D van de Biessen; M den Hollander; M Tascilar; J Verweij; H Gelderblom; S Sleijfer
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

Review 10.  Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

Authors:  N Murukesh; C Dive; G C Jayson
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.